Frazier Healthcare Surpasses Fund Target, Raises $377M Healthcare Fund

Frazier Healthcare Surpasses Fund Target, Raises $377M Healthcare Fund

September 30, 2013

Frazier Healthcare, a leading provider of growth buyout and venture capital to emerging healthcare companies, announces the closing of its seventh healthcare fund, Frazier Healthcare VII (FH VII). FH VII surpassed its target of $300 million with commitments of $377 million. FH VII investors are comprised of corporate and public pension plans, foundations, endowments, and fund of funds.

"We are very appreciative of the support that we received from existing limited partners and pleased to have brought in a number of high quality new limited partners into FH VII" comments Jamie Topper, General Partner and co-lead of Frazier's Biopharma Venture practice.

In conjunction with Frazier Healthcare VII's closing, Brian Morfitt will be  promoted to General Partner and Ben Magnano will be promoted to Partner. Brian joined Frazier in 2003 from Summit Partners and Ben joined Frazier in 2006 from Morgan Stanley Venture Partners. Both individuals have contributed significantly to the formation and success of several growth buyout investments. In addition, Dan Estes will be promoted to Vice President. Dan joined Frazier in 2011 from McKinsey & Company and is a member of Frazier's Biopharma team.

He has been instrumental with assisting in the review and investment of several portfolio companies such as Semnur Pharmaceutical and Atterocor where he is a board observer.

About Frazier Healthcare

Founded in 1991, Frazier Healthcare is a leading provider of growth buyout and venture capital to emerging healthcare service and biopharma companies. With over $2 billion under management across seven funds, Frazier Healthcare has invested in more than 150 companies across the entire developmental spectrum. From venture investments to leveraged recapitalizations, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful healthcare companies.

For more information about Frazier Healthcare, visit the company's website at

Press Contacts

Frazier Healthcare

Bridget Rauvola – Marketing & Investor Relations

Phone: 206.254.116

Cell: 303.775.2929

Email:[email protected]


Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.